Stanford University enters licence agreement for EGF technology

Stanford University has entered into a licensing agreement with Madenco Biosciences to develop and commercialise patented epidermal growth factor (EGF) wound healing technology.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Tribal business settles Stanford opioid treatment clash

29 November 2022 Dispute centred on patented data to treat opioid addiction | Tribe said it had shared confidential data to develop a cure | Stanford University.

Americas

Fed Circuit rejects Stanford Uni’s ‘abstract’ genetics patent

15 March 2021 Stanford University can’t patent a genetic testing method as it is based on “abstract mathematical calculations”, the US Court of Appeals for the Federal Circuit has ruled.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Stanford University enters licence agreement for EGF technology

More on this story

Editor's picks

Editor's picks

More features